These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 9522159

  • 1. Halofuginone: a novel antifibrotic therapy.
    Pines M, Nagler A.
    Gen Pharmacol; 1998 Apr; 30(4):445-50. PubMed ID: 9522159
    [Abstract] [Full Text] [Related]

  • 2. Halofuginone--an inhibitor of collagen type I synthesis--prevents postoperative formation of abdominal adhesions.
    Nagler A, Rivkind AI, Raphael J, Levi-Schaffer F, Genina O, Lavelin I, Pines M.
    Ann Surg; 1998 Apr; 227(4):575-82. PubMed ID: 9563549
    [Abstract] [Full Text] [Related]

  • 3. Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma.
    Pines M, Snyder D, Yarkoni S, Nagler A.
    Biol Blood Marrow Transplant; 2003 Jul; 9(7):417-25. PubMed ID: 12869955
    [Abstract] [Full Text] [Related]

  • 4. Halofuginone, an inhibitor of collagen type I synthesis, prevents postoperative adhesion formation in the rat uterine horn model.
    Nagler A, Genina O, Lavelin I, Ohana M, Pines M.
    Am J Obstet Gynecol; 1999 Mar; 180(3 Pt 1):558-63. PubMed ID: 10076128
    [Abstract] [Full Text] [Related]

  • 5. Reduction in dermal fibrosis in the tight-skin (Tsk) mouse after local application of halofuginone.
    Pines M, Domb A, Ohana M, Inbar J, Genina O, Alexiev R, Nagler A.
    Biochem Pharmacol; 2001 Nov 01; 62(9):1221-7. PubMed ID: 11705455
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of collagen type I synthesis by skin fibroblasts of graft versus host disease and scleroderma patients: effect of halofuginone.
    Halevy O, Nagler A, Levi-Schaffer F, Genina O, Pines M.
    Biochem Pharmacol; 1996 Oct 11; 52(7):1057-63. PubMed ID: 8831725
    [Abstract] [Full Text] [Related]

  • 7. Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine-induced liver cirrhosis.
    Pines M, Knopov V, Genina O, Lavelin I, Nagler A.
    J Hepatol; 1997 Aug 11; 27(2):391-8. PubMed ID: 9288615
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effect of halofuginone on the development of tight skin (TSK) syndrome.
    McGaha T, Kodera T, Phelps R, Spiera H, Pines M, Bona C.
    Autoimmunity; 2002 Jul 11; 35(4):277-82. PubMed ID: 12482197
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Topical treatment of cutaneous chronic graft versus host disease with halofuginone: a novel inhibitor of collagen type I synthesis.
    Nagler A, Pines M.
    Transplantation; 1999 Dec 15; 68(11):1806-9. PubMed ID: 10609960
    [Abstract] [Full Text] [Related]

  • 13. Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts.
    McGaha TL, Phelps RG, Spiera H, Bona C.
    J Invest Dermatol; 2002 Mar 15; 118(3):461-70. PubMed ID: 11874485
    [Abstract] [Full Text] [Related]

  • 14. Halofuginone: an inhibitor of collagen type I synthesis.
    Granot I, Halevy O, Hurwitz S, Pines M.
    Biochim Biophys Acta; 1993 Feb 13; 1156(2):107-12. PubMed ID: 8427869
    [Abstract] [Full Text] [Related]

  • 15. Topically applied halofuginone, an inhibitor of collagen type I transcription, reduces peritendinous fibrous adhesions following surgery.
    Nyska M, Nyska A, Rivlin E, Porat S, Pines M, Shoshan S, Nagler A.
    Connect Tissue Res; 1996 Feb 13; 34(2):97-103. PubMed ID: 8909874
    [Abstract] [Full Text] [Related]

  • 16. Halofuginone inhibition of COL1A2 promoter activity via a c-Jun-dependent mechanism.
    McGaha TL, Kodera T, Spiera H, Stan AC, Pines M, Bona CA.
    Arthritis Rheum; 2002 Oct 13; 46(10):2748-61. PubMed ID: 12384935
    [Abstract] [Full Text] [Related]

  • 17. The effect of halofuginone, an inhibitor of collagen type i synthesis, on urethral stricture formation: in vivo and in vitro study in a rat model.
    Nagler A, Gofrit O, Ohana M, Pode D, Genina O, Pines M.
    J Urol; 2000 Nov 13; 164(5):1776-80. PubMed ID: 11025768
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of collagen synthesis and changes in skin morphology in murine graft-versus-host disease and tight skin mice: effect of halofuginone.
    Levi-Schaffer F, Nagler A, Slavin S, Knopov V, Pines M.
    J Invest Dermatol; 1996 Jan 13; 106(1):84-8. PubMed ID: 8592087
    [Abstract] [Full Text] [Related]

  • 19. Reduction in pulmonary fibrosis in vivo by halofuginone.
    Nagler A, Firman N, Feferman R, Cotev S, Pines M, Shoshan S.
    Am J Respir Crit Care Med; 1996 Oct 13; 154(4 Pt 1):1082-6. PubMed ID: 8887611
    [Abstract] [Full Text] [Related]

  • 20. Halofuginone does not reduce fibrosis in bleomycin-induced lung injury.
    Tzurel A, Segel MJ, Or R, Goldstein RH, Breuer R.
    Life Sci; 2002 Aug 23; 71(14):1599-606. PubMed ID: 12137906
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.